NCT07577323Not yet recruiting
Safety and Efficacy Evaluation of Non-invasive Temporal Interference Stimulation for Blood Pressure Modulation in Patients With Mild Essential Hypertension
Safety and Efficacy Evaluation of Non-invasive Temporal Interference Stimulation for Blood Pressure Modulation in Patients With Mild Essential Hypertension: A Prospective, Double-blind, Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 11 May 2026
Brief summary (registry, in English)
The primary objective of this research is to study the efficacy and safety of temporal interference stimulation for blood pressure modulation in patients with mild essential hypertension.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 4 May 2026
- Start date
- 6 May 2026
- Primary completion date
- 31 May 2027
- Lead sponsor
- Xuanwu Hospital, Beijing
- Diseases
- High blood pressure
- NCT number
- NCT07577323
What you commit to
- Study type: Interventional
- Planned participants: 60
- From 6 May 2026 to the primary completion date, 31 May 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants enrolled in other clinical trials within 3 months prior to randomization.
Other illness
- Known or suspected secondary hypertension.
- Contraindications to TI treatment or sham TI treatment, including intracranial metal implants (e.g., pacemaker, ventriculoperitoneal shunt, vascular clip), craniocerebral surgery within the last 6 months, history of intracranial tumor or hemorrhage; skin damage, infection, eczema or allergy at the stimulation site (frontal/temporal region); severe skin diseases (e.g., psoriasis).
- Subjects with high risk of cerebrovascular disease indicated by cranial magnetic resonance imaging.
- History of myocardial infarction or cerebral infarction.
- Atrial fibrillation or other severe arrhythmias, such as severe bradycardia, third-degree atrioventricular block, or ventricular tachycardia.
- Individuals unable to cooperate due to mental illness or other reasons.
Lab values
- Severe or unstable medical conditions, including severe hepatic dysfunction (defined as alanine transaminase or aspartate transaminase level more than 2 times the upper limit of normal), severe renal dysfunction (defined as serum creatinine level more than 1.5 times the upper limit of normal), and severe heart failure (New York Heart Association Class III and IV).
Other
- Females who are pregnant, breastfeeding, or planning to become pregnant within one year.
- Participants deemed ineligible for this trial for other reasons determined by the investigator.
Who the study is looking for
- Aged between 30 and 65 years old.
- Office blood pressure with systolic blood pressure (SBP) 140-159 mmHg and/or diastolic blood pressure (DBP) 90-99 mmHg.
- No intake of any antihypertensive drugs or have discontinued antihypertensive medication for at least 3 months prior to randomization; no intention to receive any other antihypertensive therapy within the 15-week study period.
- Written informed consent has been obtained from the subject or their legally authorized representative after being informed of the potential risks.
Age in the registry: 30 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Xuanwu Hospital, Capital Medical University Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.